Pricing Log in Create free account

CorMedix Inc (CRMD) vs Relmada Therapeutics, Inc. (RLMD)

CorMedix Inc and Relmada Therapeutics, Inc. are both Biotechnology companies. CorMedix Inc and Relmada Therapeutics, Inc. are of similar size ($455.5M and $433.4M). Relmada Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 2.3×. CorMedix Inc has the higher net margin (40.5% vs 0.00%) and the higher return on invested capital (38.8% vs 0.00%). Across the 14 metrics below, CorMedix Inc leads on 12 and Relmada Therapeutics, Inc. on 2.

Valuation

Metric CRMD RLMD Biotechnology median
P/E 2.28 n/m 10.64
P/S 0.93 n/m 9.59
P/B 0.94 2.32 2.15
Price to free cash flow 1.72 n/m 26.07
EV/EBITDA 1.26 n/m 0.65
EV/Sales 0.69 n/m 9.45
Earnings yield 43.82% (22.37%) (34.69%)
Free cash flow yield 58.04% (26.54%) (24.02%)

Profitability

Metric CRMD RLMD Biotechnology median
Gross margin 82.78% 0.00% 65.59%
Operating margin 46.95% 0.00% 0.00%
Net margin 40.49% 0.00% 0.00%
Free cash flow margin 54.17% 0.00% 0.00%
Return on equity 54.93% (55.66%) (51.96%)
Return on assets 32.36% (51.57%) (46.06%)
Return on invested capital 38.84% 0.00% 0.00%

Growth

Metric CRMD RLMD Biotechnology median
Revenue growth (TTM) 280.50% — 4.59%
EPS growth (last fiscal year) 780.00% 45.28% 29.88%
Revenue growth, 5-year CAGR 305.79% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRMD RLMD Biotechnology median
Debt to equity 0.32 0.00 0.00
Current ratio 2.56 29.52 4.86
Net debt to EBITDA (0.02) 1.57 1.01

Dividend

Metric CRMD RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric CRMD RLMD Biotechnology median
Market cap 433.37m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack